Association between response to antidepressant treatment and genetic polymorphisms was examined in two independent Japanese samples of patients with major depressive disorder (MDD). Genome-wide approach using the Illumina Human CNV370-quad Bead Chip was utilized in the analysis of the 92 MDD patients in the first sample. In all, 11 non-intergenic singlenucleotide polymorphisms with uncorrected allelic P-value o0.0001 were selected for the subsequent association analyses in the second sample of 136 MDD patients. Difference in allele distribution between responders and nonresponders were found in the second-stage sample for rs365836 and rs201522 of the CUX1 gene (P ¼ 0.005 and 0.004, respectively). The allelic P-values for rs365836 and rs201522 in both samples combined were 0.0000023 and 0.0000040, respectively. Our results provide the first evidence that polymorphisms of the CUX1 gene may be associated with response to antidepressant treatment in Japanese patients with MDD.
INTRODUCTION
Response to antidepressant treatment varies markedly between individuals. The genetic predictors of treatment response have been intensively searched for in recent years. However, previous pharmacogenetic studies on antidepressant response have not yielded consistent results.
Three previous studies have implemented genome-wide approaches to detect single-nucleotide polymorphisms (SNPs) associated with antidepressant response. Garriock et al. 1 identified SNPs associated with response to citalopram near the ubiquitin protein ligase E3C (UBE3C) gene (P ¼ 4.65 Â 10
À7
) and the bone morphogenic protein 7 (BMP7) gene (P ¼ 3.45 Â 10
À6
). Ising et al. 2 reported an SNP in the cadherin-17 (CDH17) gene to be associated with early partial response (P ¼ 7.6 Â 10 À7 ). The Genome-based Therapeutic Drugs for Depression (GENDEP) study, 3 which was specifically designed for pharmacogenetic investigation, reported an SNP in the uronyl 2-sulfotransferase (UST) gene associated with nortriptyline response (P ¼ 3.56 Â 10 À8 ) and an SNP in the interleukin-11 (IL11) gene associated with escitalopram response (P ¼ 2.83 Â 10
). The concordance to antidepressant response in members of the same family 4 suggests a genetic component. However, the published genome-wide association studies (GWAS) failed to identify SNPs consistently associated with antidepressant response. In this study, a genome-wide approach was implemented for selecting the candidate SNPs associated with antidepressant response. Although the small GWAS sample was not appropriate for the purpose of detecting the genome-wide significance, the results of the GWAS were employed to narrow down the candidate polymorphisms for the subsequent analysis using an independent sample.
MATERIALS AND METHODS Subjects
The first-stage GWAS sample consisted of 92 patients with major depressive disorder (MDD) that completed 8 weeks of antidepressant treatment. Subjects were recruited from the outpatient clinics in Tokyo, Japan. The second sample for the candidate SNP analysis consisted of 136 patients with MDD that completed 8 weeks of antidepressant treatment and were recruited from the outpatient clinics in Kyushu, Japan. All subjects in the first and the second sample were biologically unrelated Japanese individuals. Consensus diagnosis by at least two psychiatrists was made for each patient according to the Diagnostic and Statistical Manual of Mental Disorders, 4th edition criteria, 5 on the basis of unstructured interviews and information from medical records. Participants were excluded if they had prior medical histories of central nervous system diseases or severe head injury or if they met the criteria for substance abuse or dependence or mental retardation. The study protocol was approved by the institutional ethics committees. After describing the study, written informed consent was obtained from every subject.
The severity of depression was assessed by trained psychiatrists by use of the Japanese version of the GRID Hamilton Rating Scale for Depression (HAM-D), 17-item version, 6 which has been demonstrated to show excellent inter-rater reliability. 7 Patients with HAM-D score X15 were enrolled in the study. All patients were treated with a single antidepressant medication. The patients in the first sample were prescribed one of the following antidepressants: paroxetine, fluvoxamine, nortriptyline or milnacipran. The patients in the second sample were prescribed either paroxetine or sertraline. No concomitant psychotropic medications were allowed aside from benzodiazepines and hypnotics. Responders were defined as those whose HAM-D score on their 8-week clinical visit showed %50% reduction compared to baseline.
Genotyping of the genome-wide scan Genomic DNA was prepared from the venous blood according to standard procedures. A total of 92 samples were genotyped using the Illumina Human 370-quad bead chip (Illumina, San Diego, CA, USA). A total of 356 075 autosomal SNPs were assessed for quality. SNPs were excluded if the call rate was o95%, minor allele frequency was o0.01 or the deviation from Hardy--Weinberg equilibrium was at an error level of Po0.001. The remaining 291 512 SNPs were available for analysis. The total genotyping rate was 99.8%.
Candidate SNP selection P ¼ 0.0001 was used for the cutoff value of the first-stage GWAS. Assuming a minor allele frequency of 0.3 in nonresponders and a relative risk of 1.5 of the minor allele being the risk allele of being a responder, the power to detect association was 11.4%. Assuming the same minor allele frequency and a relative risk of 2.0, the power increased to 62.8%. Intergenic SNPs were defined as SNPs that are located at least 0.5 kb 3 0 to or 2 kb 5 0 to a gene included in the HapMap data set release 28 (http://hapmap. ncbi.nlm.nih.gov/). All 11 non-intergenic SNPs with P-values below the cutoff P ¼ 0.0001 were included in the subsequent second-stage analysis.
Genotyping of the second-stage sample Genomic DNA of 136 subjects was prepared from venous blood according to standard procedures. The SNPs were genotyped using the TaqMan 5 0 -exonuclease allelic discrimination assay. Thermal cycling conditions for polymerase chain reaction were one cycle at 95 1C for 10 min, followed by 50 cycles of 92 1C for 15 s and 60 1C for 1 min. The allele-specific fluorescence was measured with ABI PRISM 7900 Sequence Detection Systems (Applied Biosystems, Foster city, CA, USA). Genotype data were read blind to the case--control status. Ambiguous genotype data were not included in the analysis. In three subjects, none of the SNPs were successfully genotyped and thus were excluded from the subsequent analyses. The call rate for each SNP ranged from 97.0 to 100%. The genotyping failure rate for all SNPs combined was 1.6%.
Statistical analysis
Treatment outcome was evaluated binary and the association with genotypes and alleles were assessed by w 2 test for independence. Deviations of genotype distributions from the Hardy--Weinberg equilibrium were assessed with the w 2 test for goodness of fit. These statistical analyses were performed using PLINK v.1.07. 8 Differences between groups were compared using t-tests for continuous variables and w 2 or Fisher's exact test for categorical variables using the Statistical Package for the Social Sciences (SPSS) v.11.0 (SPSS Japan, Tokyo, Japan). All statistical tests were two-tailed, and Po0.05 indicated statistical significance, unless otherwise specified.
RESULTS

Demographics
In the first-stage GWAS, 61 and 31 subjects were responders and nonresponders, respectively. In the second sample for the candidate SNP analysis, 82 and 54 subjects were responders and nonresponders, respectively. The demographic characteristics are shown in Table 1 . No significant difference was observed between responders and nonresponders in age, gender, depression subtype, the type of antidepressant used and the baseline HAM-D score. 
DISCUSSION
This study examined the association between response to antidepressant treatment and genetic polymorphisms in two independent Japanese samples of patients with MDD. Although none of the SNPs reached the Bonferroni-corrected genome-wide significance of Po1.7 Â 10 À7 in the GWAS, rs385836 and rs201522 of the CUX1 gene with Po0.0001 in the GWAS were also found to be significantly associated with response to antidepressant in the second sample.
The three previous studies, 1--3 using genome-wide approaches to detect genetic variations associated with antidepressant response, have not succeeded in identifying consistently significant SNPs. Although they have produced statistically significant associations between genetic polymorphisms and antidepressant response, the small effect size necessitates even larger sample size and high-quality studies. Determining which previous GWAS findings merit pursuit is not an easy task. Furthermore, none of the previous pharmacogenetic studies of antidepressant response in a Japanese population has utilized a genome-wide approach. Abbreviations: Chr, chromosome; L95, lower limit of 95% confidence interval of OR; MAF, minor allele frequency; OR, odds ratio; s.e., standard errors; SNP, single-nucleotide polymorphism; U95, upper limit of 95% confidence interval of OR.
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Therefore, we performed a GWAS in our own sample and used its results to select the candidate SNPs for the subsequent analysis.
To our knowledge, this study is the first to attempt a genomewide approach to examine the association of genetic variations and antidepressant response in an Asian population. The homogeneous sample specifically recruited for a pharmacogenetic investigation is one of the strength of this study. The unduly small sample size of the genome-wide association analysis was inappropriate for detecting genome-wide significant findings. Assuming a minor allele frequency of 0.3 in nonresponders and a relative risk of 1.5--2.0, however, the selection of SNPs with Po0.0001 gave 11.4--62.8% sensitivity for detecting associated SNPs while excluding 99.99% of the unassociated SNPs. Therefore, utilization of our GWAS data was helpful for narrowing down the candidate SNPs.
The list of SNPs with Po0.0001 in the GWAS included SNPs from both of the two Cux (also known as Cut and CDP) genes known in humans. The second-stage analysis revealed that the polymorphisms of CUX1 were significantly associated with antidepressant response. Cux proteins are a family of transcription factors involved in the regulation of cellular proliferation and differentiation (reviewed in Nepveu, 9 Sansregret and Nepveu 10 and Hulea and Nepveu 11 ). Cux plays a critical role in regulating neuronal function and cognition by controlling dendritic structures. 11--13 In humans, two Cux genes, CUX1 14 and CUX2, 15 have been identified. Studies in mice showed that CUX1 was expressed in many somatic tissues and also in the brain, 16 whereas expression of CUX2 was restricted to neural tissue. 17 Both CUX1 and CUX2 are known to be expressed in postmitotic pyramidal neurons of upper cortical layers and in precursor cells of the proliferative ventricular and subventricular zones in the mouse cerebral cortex.
18--21 CUX2 particularly regulates the proliferation of intermediate neuronal precursors in the subventricular zone of the developing brain. 22 CUX2 deletion in mice resulted in altered dendritogenesis, synaptogenesis and spine formation in pyramidal glutamatergic/GABAergic neurons. 12 It is worth noting that a previous study has provided evidence for association between bipolar disorder and genetic variations of CUX2 gene. 23 If Cux plays a role in the pathogenesis of bipolar disorder, it is reasonable that it may also affect antidepressant response in depressive patients, as unrecognized bipolar disorder is considered to be a contributor to apparent treatment-resistant depression. 24 An alternative explanation can be that a common genetic factor may be associated with treatment-resistant unipolar depression and bipolar disorder.
In contrast to CUX2, which is expressed only in neurons, 17 CUX1 is expressed in many somatic tissues. 16 However, CUX1 also has a specific role in the development of cortical pyramidal neurons. A recent study in rats showed that CUX1, but not CUX2, can regulate dendritic morphology of cortical pyramidal neurons by reducing the dendritic complexity. 25 The results of this study must be interpreted cautiously in light of the following limitations. First, the small sample size of the GWAS may have missed a large proportion of truly associated SNPs. Although Po0.0001 would include a certain proportion of associated SNPs while excluding a high percentage of unrelated SNPs, the power would be further decreased if the relative risk of the associated SNP is smaller than assumed. Next, only the non-intergenic SNPs with Po0.0001 in the GWAS results were re-examined in the second sample. Another limitation is the heterogeneity of antidepressant treatment types used. However, these antidepressants have common mechanisms of action, that is, the enhancement of monoaminergic neurotransmission. Therefore, the influence of drug-specific genetic effects may be negligible. However, our findings are limited by the absence of a placebo-comparison group, which did not allow us to determine whether the improvement was a natural course or due to the effect of antidepressants. Furthermore, as mentioned in the previous paragraph, the inclusion of patients with unrecognized bipolar depression may have also affected the results.
Our results provide the first evidence that SNPs of the CUX1 gene may be associated with response to antidepressant treatment in Japanese patients with MDD. This study effectively utilized a genome-wide approach for the selection of the SNPs for Possible association of CUX1 gene polymorphisms in MDD D Sasayama et al
